BJH - volume 12, issue 4, june 2021
R. Dewaide MD, R. Van Dijck MD, I. Vrelust MD
Introduction: BCR-ABL positive acute myeloid leukaemia is recognised as a provisional entity in the WHO 2016 classification for AML and related precursor neoplasms. Myeloid sarcoma is an extramedullary accumulation of immature myeloid cells, intracranial occurrence is rare.
Case report: A 40-year old male presented with an intracranial mass and peripheral blood blastosis of 65%. A diagnosis of acute myeloid leukaemia with intracranial myeloid sarcoma was presumed, requiring urgent cranial decompression. The patient received standard AML induction therapy with daunorubicine and cytarabine. Molecular analysis surprisingly revealed BCR-ABL positivity.
Discussion: BCR-ABL positive AML is a rare entity and needs to be differentiated from CML in blast crisis because of therapeutic consequences. In our case, clinical and molecular features suggested a diagnosis of AML.
Conclusion: To the best of our knowledge, this is the first case of intracranial myeloid sarcoma as a concurrent presentation of BCR-ABL-positive acute myeloid leukaemia.
(BELG J HEMATOL 2021;12(4):165-8)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
